Article Text

Download PDFPDF

Difference between Enbrel and Benepali treatment groups in ‘hepatobiliary disorders’
  1. Morton Scheinberg1,
  2. Valderilio Azevedo2
  1. 1Section of Rheumatology-Orthopedics, Hospital Israelita Albert Einstein, São Paulo, Brazil
  2. 2Rheumatology Section, Universidade Federal do Parana, Rebouças-Paraná, Brazil
  1. Correspondence to Professor Morton Scheinberg, Department of Rheumatology, Hospital Israelita Albert Einstein, Av Albert Einstein, São Paulo, Brazil; morton{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the study from Emery et al1 reporting the phase III trial comparing the biosimilar SB4 with originator etanercept, as well as the summary for the public that appeared in the European Public Assessment Report (EPAR)2 issued by European Medicines Agency on 28 January 2016. In our reading of the documents, we were …

View Full Text

Linked Articles